Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus

被引:142
作者
Tsang-A-Sjoe, Michel W. P. [1 ]
Bultink, Irene E. M. [1 ]
Heslinga, Maaike [1 ]
Voskuyl, Alexandre E. [1 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, Amsterdam, Netherlands
关键词
systemic lupus erythematosus; damage accrual; flare; remission; low disease activity; lupus low disease activity state; glucocorticoids; lupus nephritis; cohort study; 3; ETHNIC-GROUPS; TREAT-TO-TARGET; ORGAN DAMAGE; COHORT; INDEX; PREDICTOR; MORTALITY; PATTERNS; OUTCOMES;
D O I
10.1093/rheumatology/kew377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To identify predictors of organ damage and specifically the relationship between prolonged disease remission or low disease activity and damage accrual in a longitudinal cohort of SLE patients. Methods. Data were prospectively assessed including the occurrence of minor/major flares. Once a year remission and Lupus Low Disease Activity State (LLDAS) were determined retrospectively. A prediction model for damage accrual during follow-up was constructed with backward logistic regression analyses. Secondly, odds ratios (ORs) for damage accrual (SLICC damage index increase of >= 1 during follow-up) were calculated for patients with or without prolonged remission during 5 years, and with or without LLDAS in >= 50% of observations. Results. Data from 183 patients with a median follow-up duration of 5.0 years were analysed. The most significant predictors for damage accrual were: occurrence of >= 1 major flare, mean daily prednisone dose during follow-up and nephrological manifestations at baseline. Prolonged remission was present in 32.5% (38/117) and LLDAS in >= 50% of observations in 64.5% (118/183) of patients. Both the presence of prolonged remission during 5 years and LLDAS in >= 50% of observations were associated with a reduced risk of damage accrual (OR = 0.20, 95% CI: 0.07, 0.53, P = 0.001 and OR = 0.52, 95% CI: 0.28, 0.99, P = 0.046, respectively). Conclusion. This cohort study shows that prolonged remission and LLDAS were associated with an improved outcome, as determined by yearly assessments. In order to improve the outcome in SLE patients, future studies should investigate whether these targets can be reached actively with therapeutic strategies.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
[41]   Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study [J].
Tani, Chiara ;
Zucchi, Dina ;
Haase, Isabell ;
Larosa, Maddalena ;
Crisafulli, Francesca ;
Strigini, Francesca A. L. ;
Monacci, Francesca ;
Elefante, Elena ;
Mucke, Johanna ;
Choi, May Y. ;
Andreoli, Laura ;
Iaccarino, Luca ;
Tincani, Angela ;
Doria, Andrea ;
Fischer-Betz, Rebecca ;
Mosca, Marta .
RHEUMATOLOGY, 2021, 60 (12) :5610-5619
[42]   Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus [J].
Morand, Eric F. ;
Abreu, Gabriel ;
Furie, Richard A. ;
Golder, Vera ;
Tummala, Raj .
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (05) :639-645
[43]   Prognostic Factors at Diagnosis Associated With Damage Accrual in Childhood-Onset Systemic Lupus Erythematosus Patients [J].
Rodriguez-Lozano, Ana Luisa ;
Rivas-Larrauri, Francisco Eduardo ;
de la Puente, Silvestre ;
Alcivar-Arteaga, Daniel Alfredo ;
Gonzalez-Garay, Alejandro Gabriel .
FRONTIERS IN PEDIATRICS, 2022, 10
[44]   Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study [J].
Fasano, Serena ;
Margiotta, Domenico Paolo Emanuele ;
Pierro, Luciana ;
Navarini, Luca ;
Riccardi, Antonella ;
Afeltra, Antonella ;
Valentini, Gabriele .
CLINICAL RHEUMATOLOGY, 2019, 38 (02) :457-463
[45]   The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual [J].
Chitpet, Patamarwadee ;
Chaiamnuay, Sumapa ;
Narongroeknawin, Pongthorn ;
Asavatanabodee, Paijit ;
Leosuthamas, Pornsawan ;
Pakchotanon, Rattapol .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (12) :2509-2516
[46]   Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus [J].
Parodis, Ioannis ;
Johansson, Petter ;
Gomez, Alvaro ;
Soukka, Sofia ;
Emamikia, Sharzad ;
Chatzidionysiou, Katerina .
RHEUMATOLOGY, 2019, 58 (12) :2170-2176
[47]   VITAMIN D LEVELS ARE ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY [J].
Bojinca, Violeta ;
Popescu, Claudiu C. ;
Saulescu, Ioana Cristina ;
Opris, Daniela ;
Borangiu, Andreea ;
Groseanu, Laura ;
Balanescu, Andra ;
Ionescu, Ruxandra ;
Bojinca, Mihai .
FARMACIA, 2016, 64 (03) :423-429
[48]   High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus [J].
Formiga, F ;
Moga, I ;
Pac, M ;
Mitjavila, F ;
Rivera, A ;
Pujol, R .
RHEUMATOLOGY, 1999, 38 (08) :724-727
[49]   Seasonal vitamin D levels and lupus low disease activity state in systemic lupus erythematosus [J].
Kim, Ji-Won ;
Baek, Wook-Young ;
Jung, Ju-Yang ;
Kim, Hyoun-Ah ;
In Yang, Cheong ;
Kim, Seung-Ju ;
Suh, Chang-Hee .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (01)
[50]   The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients [J].
McCarthy, Eoghan M. ;
Smith, Siobhan ;
Lee, Ruth Z. ;
Cunnane, Gaye ;
Doran, Michele F. ;
Donnelly, Suzanne ;
Howard, Donough ;
O'Connell, Paul ;
Kearns, Grainne ;
Gabhann, Joan Ni ;
Jefferies, Caroline A. .
RHEUMATOLOGY, 2014, 53 (09) :1586-1594